Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Mood Disorders Society of Canada Survey

Wake Up Narcolepsy Selected as July’s Hannaford Community Bag Program Beneficiary

Showcasing Community Voices at the 2026 SLEEP Meeting

Findings From the Institute for Clinical and Economic Review (ICER) Now Available

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Future Neurology “Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication”

The Power of Being Seen: Narcolepsy and Mental Health

High Blood Pressure Doesn’t Sleep — What You Should Know

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia